Evolution of the Average Target: United Therapeutics Corporation

Evolution of the Average Target - United Therapeutics Corporation

Evolution of the Target Price: United Therapeutics Corporation

Evolution of the Target Price - United Therapeutics Corporation

Changes in Analyst Recommendations: United Therapeutics Corporation

aea3.402KHNZcQ0e3aH8IwnzuJURoRptoKL_UjIIh_TdisJw.lhTtW6A9GnGaPCUwhjCHFgctLO8KW_K2-LBSh3032dq7O91DlA0nL9olCA~e7cc117540172da87e94e89f7008fcc3
11-05 RBC Raises Price Target on United Therapeutics to $725 From $697, Keeps Outperform Rating MT
10-22 United Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC Says MT
10-22 RBC Trims Price Target on United Therapeutics to $697 From $708, Keeps Outperform Rating MT
10-08 RBC Raises Price Target on United Therapeutics to $708 From $677, Keeps Outperform Rating MT
10-01 Liquidia Shares Drop After Downgrades From Raymond James, BTIG MT
10-01 BTIG Upgrades United Therapeutics to Buy From Neutral, Price Target is $728 MT
08-06 MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says MT
08-06 United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says MT
08-06 RBC Capital Adjusts PT on United Therapeutics to $677 From $704, Maintains Outperform Rating MT
08-06 Morgan Stanley Adjusts PT on United Therapeutics to $515 From $516, Maintains Equalweight Rating MT
07-10 Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says MT
07-10 BofA Securities Adjusts United Therapeutics Price Target to $613 From $620 MT
07-07 RBC Capital Raises United Therapeutics Price Target to $704 From $701, Maintains Outperform Rating MT
06-30 United Therapeutics IPF Opportunity Outweighs Base Business Risks, UBS Says MT
05-07 United Therapeutics Growth Outlook Remains Supported by Tyvaso, Ralinepag, RBC Says MT
05-07 RBC Capital Adjusts United Therapeutics Price Target to $701 From $707, Maintains Outperform Rating MT
05-07 Wells Fargo Upgrades United Therapeutics to Overweight From Equalweight, Raises Price Target to $738 From $575 MT
05-07 Morgan Stanley Trims Price Target on United Therapeutics to $516 From $519, Keeps Equalweight Rating MT
04-10 Raymond James Initiates United Therapeutics at Outperform MT
04-07 RBC Capital Adjusts Price Target on United Therapeutics to $700 From $643, Maintains Outperform Rating MT
03-05 United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says MT
03-05 UBS Adjusts Price Target on United Therapeutics to $705 From $655, Maintains Buy Rating MT
02-26 United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says MT
02-26 Oppenheimer Adjusts United Therapeutics Price Target to $600 From $575, Maintains Outperform Rating MT
02-26 RBC Raises Price Target on United Therapeutics to $643 From $587, Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+17.64%
+3.75%
+0.53%
+7.88%
-2.27%
+12.66%
-3.15%
+18.14%
-5.48%
+3.33%
Average +5.30%
Weighted average by Cap. +3.93%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
584.10USD
Average target price
687.14USD
Spread / Average Target
+17.64%
High Price Target
850.00USD
Spread / Highest target
+45.52%
Low Price Target
390.00USD
Spread / Lowest Target
-33.23%

Analyst Consensus Detail

Analyst consensus - United Therapeutics Corporation

Consensus revision (last 18 months)

Consensus revision (last 18 months) - United Therapeutics Corporation
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - United Therapeutics Corporation
  1. Stock Market
  2. Stocks
  3. UTHR Stock
  4. Consensus United Therapeutics Corporation